We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Studying Inclusion of Risk/Benefit Information in DTC Advertising
FDA Studying Inclusion of Risk/Benefit Information in DTC Advertising
October 3, 2012
The FDA needs more time to make a decision about whether risk/benefit information should be added to prescription drug promotional labeling or advertising, the agency said in a recent report to Congress.